Fig. 2

Adipo-barr2-KO mice are protected against the detrimental metabolic effects caused by the consumption of a HFD. a, b In vivo metabolic tests. Control and adipo-barr2-KO mice maintained on HFD for 8–9 weeks were subjected to i.p. glucose tolerance (1 g glucose/kg; IGTT) (a) and insulin tolerance tests (1 U insulin/kg i.p.; ITT) (b) (n = 7–9/group). AUC, area under the curve. c, d Freely fed and fasting blood glucose (c) and plasma insulin levels (d) of control and adipo-barr2-KO mice maintained on HFD for 8–9 weeks (n = 7–9/group). e–g Freely fed and fasting plasma leptin (e), adiponectin (f), and resistin (g) levels in control and adipo-barr2-KO mice maintained on HFD for 12 weeks (n = 7–10/group). h–k Plasma levels of proinflammatory cytokines. MCP-1 (h), IFN-γ (i), TNF-α (j), and IL6 (k) plasma levels in control and adipo-barr2-KO mice fed with HFD for 12 weeks (n = 8–11/group). All experiments were carried out with male mice. Data are given as means ± s.e.m. *p < 0.05, **p < 0.01 (a, b two-way ANOVA followed by Bonferroni’s post hoc test or two-tailed Student’s t-test (AUC); c–k two-tailed Student’s t-test)